key: cord-0327493-r6lirt9m
authors: Kelly, S. E.; Wells, G. A.
title: Noninvasive ventilation strategies for patients with severe or critical COVID-19: A rapid review of clinical outcomes
date: 2022-05-26
journal: nan
DOI: 10.1101/2022.05.25.22275586
sha: 8ad9a0935d746f76e37280a1160403f96886b6f5
doc_id: 327493
cord_uid: r6lirt9m

Objectives: To examine whether high flow nasal oxygen (HFNO), continuous positive airway pressure (CPAP), or noninvasive ventilation (NIV) strategies impact mortality, the need for invasive mechanical ventilation (IMV), or hospital and intensive care unit (ICU) length of stay compared to standard oxygen therapy (SOT) or each other in patients with severe or critical COVID-19 with acute hypoxemic respiratory failure. Methods: A rapid review of randomized controlled trials (RCTs) identified through published systematic and rapid reviews supplemented with a search of bibliographic databases. RCTs were eligible if they compared HFNO, CPAP, or NIV to SOT or another ventilation strategy. Studies were screened, selected, and extracted by a single reviewer and checked by a second reviewer. We assessed risk of bias of included studies using the Cochrane 'Risk of bias' tool and used the grading of recommendations, assessment, development, and evaluation (GRADE) approach to judge the certainty of the evidence for mortality, need for IMV, and hospital and ICU length of stay. We sought RCT evidence for non-COVID-19 patients with acute hypoxemic respiratory failure and acute respiratory distress to inform additional comparisons and to supplement the available data for COVID-19. Results: A total of 5 RCTs comparing ventilation strategies in patients with severe or critical COVID-19 were included. Patient and study characteristics were extracted and evidence and certainty of evidence assessments were completed for comparisons of HFNO and CPAP to standard oxygen therapy and NIV and CPAP to HFNO. An additional 22 RCTs of non-COVID-19 patients were also included and considered. Results from meta-analysis suggest reductions in mortality and IMV with HFNO (RR mortality 0.87 (0.66-1.13), IMV 0.89 (0.77-1.03); low quality evidence) or CPAP (RR mortality 0.87 (0.64-1.18) low quality evidence, IMV 0.81 (0.67-0.98) moderate quality evidence) compared to SOT. Helmet NIV may reduce IMV (RR 0.69 (0.43-1.09)) and CPAP may reduce IMV (RR 0.69 (0.43-1.09)) and hospital (1.67 days fewer (5.43 fewer-2.09 more) or ICU length of stay (1.02 days fewer (3.97 fewer-1.93 more)) compared to HFNO (low quality evidence). Conclusions: This rapid systematic review highlights the available evidence to support the use of noninvasive ventilation strategies including high flow nasal oxygen, noninvasive ventiltaion (e.g., BiPAP), or CPAP in hospitalized patients with severe or critical COVID-19 and acute hypoxemic respiratory failure who do not need emergent intubation. Findings based on moderate to very low certainty evidence suggest that noninvasive ventilation may be considered as an alternative to standard oxygen therapy to reduce hypoxemia and dyspnea. Additional high quality RCTs are warranted to reduce uncertainty and to fill in important knowledge gaps.

The review team used a population, intervention, comparator, and outcomes (PICO) framework ( Table 1) .

We aimed to find, assess and synthesize all randomized controlled trials (RCTs) of severe or critical COVID- 19 and acute hypoxemic respiratory failure (AHRF). Eligible studies were RCTs of patients hospitalized with severe or critical COVID-19 and AHRF not needing emergent intubation who used HFNO, CPAP or NIV (e.g., Bilevel Positive Airway Pressure; BiPAP). Comparisons of interest were standard oxygen therapy (SOT) or another intervention of interest. The primary outcomes are mortality, need for invasive mechanical ventilation (IMV), and hospital length of stay, with intensive care unit (ICU) length of stay and patient-reported outcomes (e.g. patient comfort, satisfaction with care) are secondary outcomes. Patients weaned off IMV or those who require respiratory support following IMV were not eligible. Reviewers also sought evidence in a related clinical population of individuals with ARDS and AHRF to provide indirect evidence for the use of noninvasive ventilation in COVID-19 patients (Methods and results, Online Supplement 1).

An experienced information scientist designed and executed the literature searches.

The search first targeted systematic and rapid reviews (SR/RRs) of potentially eligible RCTs in two electronic COVID-19 databases (WHO COVID-19 Global literature on coronavirus disease database 9 , the Living OVerview of Evidence (L.OVE) platform) 10 and the COVID-END inventory 11 of best evidence syntheses for clinical management to rapidly identify eligible SR/RRs [May 2 to 3, 2021] (Online supplement 2). Reviewers checked the included study lists of the identified English language SR/RRs for potentially eligible RCTs and checked all ongoing RCT records from the SR/RRs for results (July 15, 2021) .

A second search (WHO COVID-19 study register, Cochrane COVID-19 study register, clinicaltrials.gov; May 15, 2021) sought to identify RCTs published or registered since the last identified SR/RR search (01 July 2020). The information scientist did not execute the planned search of the International Clinical Trials Registry Platform (ICTRP) 12 as the database was not accessible to our information scientist during this rapid review. We did not apply restrictions to publication status or language in the search strategy.

All ongoing studies identified were checked for results (June [15] [16] [17] [18] [19] [20] [21] 2021) . We used monthly alerts to identify additional RCT records and performed a forward citation analysis on all included records using both SCOPUS and Google Scholar. Monitoring of search alerts and ongoing RCTs continued monthly until December 29, 2021. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 26, 2022. ;  https://doi.org/10.1101/2022.05.25.22275586 doi: medRxiv preprint

All records were uploaded into EndNoteX20 13 and then into Covidence 14 for screening and selection. One reviewer screened all title and abstract records (SR/RRs and then RCTs) and confirmed the results with a second reviewer. One reviewer located and screened all potentially relevant full-text articles identified through the SR/RR and RCT searches. A second reviewer confirmed all included SR/RRs and RCTs and resolved disagreements through discussion. Reviewers used a PRISMA flow diagram to document the selection process in detail.

Included SR/RRs and RCTs directly compared two or more interventions or comparators in the PICO and reported at least one outcome of interest. We excluded studies reporting broad clinical course as it is not possible to link clinical outcomes and isolate the effect of the noninvasive ventilation strategy.

For each included SR/RR, one reviewer extracted details of the citation, synthesis approach, PICO, search dates, and the number of included potentially relevant RCTs studies into structured summary tables (Microsoft Word).

For each included RCT, one reviewer retrieved all reported participant characteristics, study characteristics and outcome data from the SR/RR publication or extracted data de novo into structured outcome tables (Microsoft Excel). A second reviewer checked all extracted data.

One reviewer appraised each included SR/RR using AMSTAR2 15 and retrieved the risk of bias (ROB) assessments for the included RCTs where reported. Otherwise, a single reviewer assessed the ROB in trials with no retrieved assessment (Cochrane ROB tool 16 ) or when the retrieved assessment did not have sufficient detail to inform the summary of findings table. ROB ratings were not used as exclusion criteria.

One reviewer constructed GRADE evidence profiles of certainty for each primary and secondary outcome and each intervention comparison, separately using MAGICapp 17 . A second reviewer checked all tables, and they were vetted by content and methodological experts. The certainty of the evidence was determined by the risk of bias across studies, inconsistency, indirectness, and imprecision 18 . Reviewers did not consider incoherence, publication bias and other parameters. We used the most recent GRADE methodology to decide on the certainty of the body of evidence from RCTs, which recommends using the judgment of high certainty of evidence at baseline and downgrading due to risk of bias, imprecision, or indirectness of . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) 18 . Minimal important differences and optimal information size (OIS; 1000 participants) were determined in advance through consult with content experts and used to inform judgements about precision. Downgrading 3 levels for precision was considered when the number of study participants for an outcome was less than 30% of the OIS 19 .

When the certainty (or quality) of evidence is rated very low or extremely low, we are very unsure about the true effect, while a rating of low certainty/quality evidence means that the true effect could be markedly different from the estimated effect. Ratings of moderate certainty indicate that reviewers feel that the true effect is probably close to the estimated effect, and high certainty ratings signify a high level of confidence in the estimated effect 20 . Plain language statements are determined based on the ratings for the certainty of evidence and are presented with the ratings.

Reviewers used Review Manager (Version 5.4; RevMan) to calculate the treatment effect for each primary and secondary outcome (risk ratios for dichotomous outcomes, mean difference for continuous outcomes).

Reviewers undertook meta-analyses when 2 studies or comparisons reported the same outcome. A fixed effects model was used for all meta-analyses and the unit of analysis was individuals. Otherwise, reviewers completed a descriptive summary of evidence by comparison and outcome. When an RCT did not directly compare the study interventions (e.g., a 3-arm study where HFNO and NIV are each compared to SOT but not to each other), the relative effects were calculated using the pooled relative effects (risk ratio) for the interventions reported to calculate an indirect estimate for the relative effects of the comparison of interest 21 .

For RCTs reporting hospital or ICU LOS outcomes both as means (standard deviation) and medians (interquartile range; IQR) for any one outcome, meta-analysis was conducted in R using the Metamedian package 22, 23 . LOS data were also checked for consideration of competing risk 24 .

The I 2 statistic was used to measure heterogeneity among the included trials. Publication bias was not assessed or small studies effects because fewer than 10 studies were included. Subgroup or sensitivity . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted May 26, 2022. ; https://doi.org/10.1101/2022.05.25.22275586 doi: medRxiv preprint analyses were not conducted, and investigators or study sponsors were not contacted to provide missing data.

A total of 342 title and abstract records and 41 full-text articles were screened for relevant SR/RRs. From these, we identified three SRs (reported in five published reports) [25] [26] [27] [28] [29] and four RRs 30-33 reporting noninvasive ventilation strategies in hospitalized patients with severe or critical COVID-19 and acute hypoxemic respiratory failure not requiring emergent intubation. Reviewers identified and included three RCTs [34] [35] [36] in three records from the included study lists of these reviews and through related forward citation tracking. An additonal search for RCTs published between July 1, 2020 (the search date from the most recent included SR) and May 15, 2021 identified 1,385 title and abstract records (including records identified by alerts). Following screening, 24 full-text articles were reviewed and two more eligible RCTs were identified 37, 38 . A total of five RCTs were included.

Three additional records reporting RCTs in-progress (NCT04326075, NCT04381923 and NCT04507802) and one terminated RCT 39 were also located but were excluded as no posted or published results were available within our search or alert time-frame.

The screening and selection process is reported in a PRISMA 2020 flow diagram modified to capture the search for SR/RRs and RCTs (Figure 1 ) 40 . The included SR/RRs and their AMSTAR2 assessments are summarized in Online Supplement 3.

A summary of the five included RCTs 34-38 is provided in Table 2 . Additional details for the study and participant characteristics are reported in Online Supplement 4. Four of the RCTs compared HFNO to standard oxygen therapy [34] [35] [36] 38 , one 3-arm RCT compared CPAP to standard oxygen therapy 35 , one 2-arm RCT compared helmet NIV to HFNO 37 and one three-arm RCT compared CPAP and HFNO 35 38 . Participants were adults admitted to the emergency department, general ward, or intensive care unit of 3 centres in Columbia. This study reported all primary and secondary outcomes of interest.

There was limited information regarding the assessed ROB of the individual RCTs to carry forward from the SR/RRs, and therefore de novo ROB assessments were individually completed (Online Supplement 5).

Mortality and IMV outcomes were considered in the assessment of blinding at the participant and personnel level, and IMV was specifically considered when blinding of outcome assessment was rated.

Participants and personnel were not blinded in any of the included RCTs (and blinding would have been difficult or impossible due to the nature of the interventions). Varying criteria may have been used within or across studies to initiate IMV. Intubation outcomes in the Grieco et al. RCT were independently adjudicated by external experts, but no adjudication of the intubation outcomes was reported in the other RCTs. Crossover or progression to other interventions or study arms and cointerventions could not be fulsomely assessed in the included RCTs, and therefore the risk of bias is unclear. Intention to treat data are extracted where available, but the effects in some patients may be attributable to multiple therapies.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) 

Evidence and certainty of evidence assessments for all comparisons and outcomes are summarized in [34] [35] [36] 38 . HFNO probably has little or no difference in ICU LOS (moderate quality evidence). None of the trials included children or pregnant women, and none reported any patient-important outcomes (e.g., comfort, satisfaction).

Evidence from five additional RCTs conducted in non-COVID patients with ARDS and AHRF (1425 participants) is generally consistent, although there is less certainty over potential differences in mortality [42] [43] [44] [45] [46] [47] .

One published RCT of 742 participants compared CPAP to SOT 35 . Based on moderate quality evidence, CPAP probably decreases IMV compared to SOT (RR 0.81, 95% CI 0.67 -0.98). There is low quality evidence that CPAP may decrease mortality (RR 0.87, 95% CI 0.64 -1.18) and hospital LOS (0.96 fewer days; 95% CI 3.59 fewer -1.67 more) and may have little or no difference in ICU LOS (0.08 fewer days, 95% CI 2.23 fewer -2.07 more; low quality evidence). The study did not report any patient-important outcomes and did not include pregnant women or children.

Four RCTs of non-COVID ARDS and AHRF patients compared CPAP to SOT [48] [49] [50] [51] . Three RCTs compared helmet CPAP interfaces to SOT (168 participants) and one RCT compared a face mask CPAP interface to SOT (123 patients) [48] [49] [50] [51] . Evidence was very uncertain for all outcomes except hospital LOS where helmet CPAP may have little or no difference compared to SOT (0.5 more days, 95% CI 3.75 fewer -4.75 more).

No RCTs compared NIV to SOT in patients with COVID-19.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) 

One RCT 35,41 enrolled 1273 participants into SOT, HFNO and CPAP arms but did not directly compare CPAP to HFNO in the trial analyses. As such, the meta-analysis for the comparison of CPAP vs. HFNO was informed by an indirect comparison (Online supplement 6). Based on these results, CPAP may decrease IMV (RR 0.69, 95% CI 0.43 -1.09), hospital (1.67 days fewer, 95% CI 5.43 fewer -2.09 more) and ICU LOS (1.02 days fewer, 95% CI 3.97 days fewer -1.93 more)(low quality evidence) but results for mortality are very uncertain (RR 0.95, 95% CI 0.52 -1.71)). The RCT did not include children or pregnant women.

This rapid systematic review followed a transparent and robust approach to locate and appraise evidence from five RCTs comparing non-invasive ventilation strategies in hospitalized patients with severe or critical COVID-19 and acute hypoxemic respiratory failure not needing emergent intubation. Additional evidence was considered from 22 RCTs of similar patients without COVID-19 who had severe respiratory distress syndrome and acute respiratory failure. Based on the available evidence for mortality, use of IMV, and hospital or ICU LOS, it may be appropriate to consider the use of HFNO, NIV or CPAP instead of standard oxygen therapy for patients with severe and critical COVID-19 who do not require emergent intubation.

None of the evidence for the outcomes of interest was assessed to be high quality using GRADE and ranged . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 26, 2022. ; https://doi.org/10.1101/2022.05.25.22275586 doi: medRxiv preprint from moderate to very low. Additional high-quality trials are required to reduce the uncertainty associated with the evidence base for the available non-invasive ventilation strategies and to eliminate knowledge gaps related to the overall generalizability of the evidence.

This data supplements two existing evidence syntheses focused only on HFNO 28 64 . Of the ongoing studies, COVID-NIV is a case-only observational study, and PAP-COVID and COVID HELMET are listed as terminated, one due to declining cases of COVID-19, and the other citing feasibility. Two RCTs (COVID-HIGH and HELMET-COVID) are still expected to produce results in 2022 or 2023. The COVID-HIGH study (NCT NCT04655638), which has completed enrollment and will provide additional outcome data for HFNO compared to standard oxygen therapy and potentially evidence to support the role of HFNO reducing the need for escalation to NIV or CPAP (n=364 participants). The HELMET-COVID trial will contribute evidence for helmet NIV compared to standard oxygen therapy, facemask NIV, HFNO. This will provide much-needed data on the use of NIV in patients aged 14 or older with COVID-19 in the ICU and potentially comparative data for the role of NIV mask or helmet interfaces. Enrollment was reported to have been completed in October of 2021.

There are several limitations in the included RCTs that should be considered alongside the findings. There was no evidence located for use of non-invasive ventilation strategies in infants or children or important subpopulations (e.g., pregnant women), very limited evidence to support the specific use of named interfaces for the ventilation strategies considered (e.g., nasal cannula, simple face mask, venturi mask, oronasal, helmet or other), and only one RCT reported patient-important outcomes. The hospital LOS data are challenging to interpret as competing risk for death may not have been appropriately accounted for in . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 26, 2022. ; https://doi.org/10.1101/2022.05.25.22275586 doi: medRxiv preprint most RCTs, or it is not possible to assess how competing risk was handled in an RCT 66 . In the set of included RCTs, the LOS outcomes are generally either secondary or exploratory outcomes, and as such, the estimates presented may be confounded by death. The LOS data for survivors and non-survivors is rarely presented. Owing to the rapid synthesis approach, there was no formal extraction or synthesis of harm outcomes.

When non-invasive ventilation supports are considered, potential benefits must be consiered alongside any conceivable harms. Use of ventilation strategies could delay other clinical intervention that could lead to worsening patient prognosis, cause discomfort to the patient during use, or result in surficial wounds or pressure sores where there is skin contact.

Care for acutely ill patients with COVID-19 is complex. Although focused on ventilation strategies, the trials included likely use these interventions in conjunction with a number of other care strategies and supports (e.g., patient in prone position, medications) that should also be noted, but were not considered in detail in this rapid review. Data were insufficient to assess the impact of intervention crossover in the included RCTs which has been flagged as a concern in previous syntheses 64 . No studies specified patient outcomes or source of infection associated with any particular SARS-COV-2 variants of concern. It has been suggested that use of non-invasive ventilation strategies may increase transmission of SARS-COV-2 to healthcare workers, placing them at risk during care and adding strain to the healthcare system when isolation is required 2,26 . Although appropriate personal protective equipment may provide adequate protection for some healthcare workers when NIV strategies are used, existing studies are predominantly from early 2020 there is a lack of comparative studies available on this topic [67] [68] [69] [70] [71] [72] [73] [74] [75] [76] [77] [78] .

The implementation of non-invasive ventilation strategies in the hospital environment must be supported by appropriate resources (including staff training, monitoring capacity) and infrastructure (e.g., interfaces or tubing, oxygen supply, cleaning or protective practices). This could prove to be challenging in some settings, particularly in low and middle income countries or settings that are acutely impacted by pandemic-related surges or supply shortages. Implementation of monitoring practices seen in the existing clinical trials may not be completely generalizable or feasible to clinical settings outside of the ICU where provider-patient ratios are higher 2 .

The evidence base is expanding and additional trials and observational studies are expected to be completed later in 2022 or early 2023. It is anticipated that studies underway will provide new information for NIV use and interfaces and provide evidence for the gaps identified in the current evidence base.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 26, 2022 Additional information related to patient important outcomes would add substantially to our knowledge and understanding of these non-invasive ventilation strategies.

This rapid systematic review highlights the available evidence to support the use of non-invasive ventilation strategies including high flow nasal oxygen, non-invasive ventilation (e.g., BiPAP) or CPAP in hospitalized patients with severe or critical COVID-19 and acute hypoxemic respiratory failure who do not need emergent intubation. Findings based on moderate to very low certainty evidence suggest that noninvasive ventilation may be considered as an alternative to standard oxygen therapy to reduce hypoxemia and dyspnea. Additional high quality RCTs are warranted to reduce uncertainty and to fill in important knowledge gaps.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 26, 2022 This project was funded in part by the World Health Organization (PO 202642154).

Project funding was augmented through existing research funds held at the University of Ottawa.

We would also like to acknowledge our patient/citizen partners Elaine Zibrowski and Maya Sterne for their review and feedback on our protocol and their ongoing support for knowledge translation activities. 

Systematic/rapid reviews b to identify eligible trials, randomized controlled trials c . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) 

COVID-19) Treatment Guidelines. National Institutes of Health

SIMEU position paper on non-invasive respiratory support in COVID-19 pneumonia

Living guidance for clinical management of COVID-19: living guidance

How to avoid interface problems in acute noninvasive ventilation

The interface: crucial for successful noninvasive ventilation

Invasive and Non-Invasive Ventilation in Patients With COVID-19

Case Fatality Rates for Patients with COVID-19

Requiring Invasive Mechanical Ventilation. A Meta-analysis

Clinical management of patients with severe or critical COVID-19 using high flow nasal oxygen (HFNO), continuous positive airway pressure (CPAP) or non-invasive ventilation (NIV)

COVID-19: Global literature on coronavirus disease

COVID-19 L· OVE repository is highly comprehensive and can be used as a single source for COVID-19 studies

COVID-END: an international network to better co-ordinate and maximize the impact of the global evidence synthesis and guidance response to COVID-19

World Health Organization. International Clinical Trials Registry Platform (ICTRP)

Version x20. Clarivate

Covidence systematic review software (Available at www.covidence.org). Veritas Health Innovation

AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both

The Cochrane Collaboration's tool for assessing risk of bias in randomised trials

MAGICapp -Making GRADE the Irresistible Choice (App.magicapp.org). The MAGIC Foundation

GRADE handbook for grading quality of evidence and strength of recommendations

GRADE guidelines 32: GRADE offers guidance on choosing targets of GRADE certainty of evidence ratings

GRADE guidelines: 11. Making an overall rating of confidence in effect estimates for a single outcome and for all outcomes

The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials

Meta-analysis of the difference of medians

One-sample aggregate data meta-analysis of medians

Analyzing factors affecting emergency department length of stay-using a competing risk-accelerated failure time model

Update Alert 2: Ventilation Techniques and Risk for Transmission of Coronavirus Disease, Including COVID-19

Ventilation Techniques and Risk for Transmission of Coronavirus Disease, Including COVID-19: A Living Systematic Review of Multiple Streams of Evidence

Update Alert: Ventilation Techniques and Risk for Transmission of Coronavirus Disease, Including COVID-19

High-flow nasal cannulae for respiratory support in adult intensive care patients. Cochrane Database Syst Rev

High-flow nasal cannula for acute hypoxemic respiratory failure in patients with COVID-19: systematic reviews of effectiveness and its risks of aerosolization, dispersion, and infection transmission

Mortality and clinical outcomes in patients with COVID-19 pneumonia treated with non-invasive respiratory support: A rapid review

EVIDENCE CHECK: Continuous Positive Airway Pressure (CPAP) machines -What is the current advice regarding for use of CPAP as a substitute for ventilators during the 2020

COVID-19 Scientific Advisory Group Rapid Response Report -Updates on Recommended Use of Noninvasive Ventilation in AHS Acute Care Facilities During the COVID-19 Pandemic. 2020

Effect of transnasal high-flow humidifying oxygen therapy for the treatment of new coronavirus pneumonia with acute respiratory failure

An adaptive randomized controlled trial of non-invasive respiratory strategies in acute respiratory failure patients with COVID-19

The value of high-flow nasal cannula oxygen therapy in treating novel coronavirus pneumonia

Effect of Helmet Noninvasive Ventilation vs High-Flow Nasal Oxygen on Days Free of Respiratory Support in Patients With COVID-19 and Moderate to Severe Hypoxemic Respiratory Failure: The HENIVOT Randomized Clinical Trial

Effect of High-Flow Oxygen Therapy vs Conventional Oxygen Therapy on Invasive Mechanical Ventilation and Clinical Recovery in Patients With Severe COVID-19: A Randomized Clinical Trial

Helmet continuous positive airway pressure versus high-flow nasal cannula in COVID-19: a pragmatic randomised clinical trial (COVID HELMET)

Declaracion PRISMA 2020: una guia actualizada para la publicacion de revisiones sistematicas

Effect of Noninvasive Respiratory Strategies on Intubation or Mortality Among Patients With Acute Hypoxemic Respiratory Failure and COVID-19: The RECOVERY-RS Randomized Clinical Trial

High-flow nasal oxygen reduces endotracheal intubation: a randomized clinical trial

Effect of non-invasive oxygenation strategies in immunocompromised patients with severe acute respiratory failure: a post-hoc analysis of a randomised trial

Randomized Controlled Trial of Humidified High-Flow Nasal Oxygen for Acute Respiratory Distress in the Emergency Department: The HOT-ER Study. Respir Care

High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure

The effects of a 2-h trial of high-flow oxygen by nasal cannula versus Venturi mask in immunocompromised patients with hypoxemic acute respiratory failure: a multicenter randomized trial

Effect of High-Flow Nasal Oxygen vs Standard Oxygen on 28-Day Mortality in Immunocompromised Patients With Acute Respiratory Failure: The HIGH Randomized Clinical Trial

Helmet CPAP vs. oxygen therapy in severe hypoxemic respiratory failure due to pneumonia

Helmet continuous positive airway pressure vs oxygen therapy to improve oxygenation in community-acquired pneumonia: a randomized

Early CPAP prevents evolution of acute lung injury in patients with hematologic malignancy

Treatment of acute hypoxemic nonhypercapnic respiratory insufficiency with continuous positive airway pressure delivered by a face mask: A randomized controlled trial

Noninvasive ventilation for treatment of acute respiratory failure in patients undergoing solid organ transplantation: a randomized trial

Acute respiratory failure in patients with severe community-acquired pneumonia. A prospective randomized evaluation of noninvasive ventilation

Noninvasive ventilation in severe hypoxemic respiratory failure: a randomized clinical trial

A multicenter RCT of noninvasive ventilation in pneumonia-induced early mild acute respiratory distress syndrome. Crit Care

Noninvasive ventilation reduces intubation in chest trauma-related hypoxemia: a randomized clinical trial. Chest

Noninvasive ventilation in immunosuppressed patients with pulmonary infiltrates, fever, and acute respiratory failure

Effect of Noninvasive Ventilation vs Oxygen Therapy on Mortality Among Immunocompromised Patients With Acute Respiratory Failure: A Randomized Clinical Trial

Respiratory failure in patients undergoing allogeneic hematopoietic SCT--a randomized trial on early non-invasive ventilation based on standard care hematology wards

Noninvasive pressure support ventilation in patients with acute respiratory failure. A randomized comparison with conventional therapy

Early use of noninvasive positive pressure ventilation for acute lung injury: a multicenter randomized controlled trial

High flow nasal cannula oxygen (hfnc) versus non-invasive positive pressure ventilation (nippv) in acute hypoxemic respiratory failure. a pilot randomized controlled trial

High-flow nasal oxygen therapy versus noninvasive ventilation in chronic interstitial lung disease patients with acute respiratory failure

Update Alert 3: Ventilation Techniques and Risk for Transmission of Coronavirus Disease, Including COVID-19

Helmet noninvasive ventilation for COVID-19 patients (Helmet-COVID): statistical analysis plan for a randomized controlled trial

Competing risk regression models for epidemiologic data

Novel percutaneous tracheostomy for critically ill patients with COVID-19. The Annals of thoracic surgery

Investigation of nosocomial SARS-CoV-2 transmission from two patients to healthcare workers identifies close contact but not airborne transmission events

Use of Helmet-Based Noninvasive Ventilation in Air Medical Transport of Coronavirus Disease

Analysis of bronchoscope-guided tracheal intubation in 12 cases with COVID-19 under the personal protective equipment with positive pressure protective hood. Zhonghua jie he he hu xi za zhi= Zhonghua jiehe he huxi zazhi= Chinese journal of tuberculosis and respiratory diseases

Healthcare workers & SARS-CoV-2 infection in India: A casecontrol investigation in the time of COVID-19

Transmission of COVID-19 to Health Care Personnel During Exposures to a Hospitalized Patient

Use of personal protective equipment against coronavirus disease 2019 by healthcare professionals in Wuhan, China: cross sectional study

Health care personnel exposure to a patient with asymptomatic SARS-CoV2 infection during a prolonged surgical intervention

COVID-19 and the risk to health care workers: a case report

Aerosolized SARS-CoV-2 transmission risk: Surgical or N95 masks?

Risk Factors of Healthcare Workers With Coronavirus Disease 2019: A Retrospective Cohort Study in a Designated Hospital of Wuhan in China

Spinal anaesthesia for patients with coronavirus disease 2019 and possible transmission rates in anaesthetists: retrospective, single-centre, observational cohort study

The authors would like to acknowledge Vijay Shukla, Shuching Hsieh, and Nathan Orr for their contributions to this rapid review. We would like to acknowledge Becky Skidmore for her assistance with the search strategy design and execution. We would like to acknowledge Michael Wilson for his assistance with records from the COVID-End database.